Clinical TrialID 988

Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

NCT02899169

Acute Promyelocytic Leukemia

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Herb: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
988
Evidence Id
988
Core Evidence Id
988
Source Clinical Trial Id
970
Herb2 Clinical Trial Id
HBCT000970
Nct Id
NCT02899169
Title
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Status
Phase
Phase 3
Study Result
No
Study Condition
Acute Promyelocytic Leukemia
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Intervention
DRUG: Realgar-Indigo naturalis formula|DRUG: all-trans retinoic acid|DRUG: Arsenic trioxide|DRUG: Hydroxyurea
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Intervention Purpose
Treatment
Gender
All
Age
Child, Adult, Older_Adult
Enrollment
110
Outcome Measure
Disease-free survival (DFS), At 2 years
Sponsor Collaborator
First Affiliated Hospital Xi'an Jiaotong University|Tang-Du Hospital
Funded By
OTHER
Location
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710016, China
Other Id
XJTU1AF2016LSL-017
Start Date
2016-09-01
Primary Completion Date
2022-09-01
Completion Date
2022-11-01
First Posted
2016-09-14
Results First Posted
Last Update Posted
2021-09-08
Study Document
Study Url
https://clinicaltrials.gov/study/NCT02899169
Title Cn
Title En
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Bilingual Status
semi_complete